Trading-Stocks.de

Merck & Co., wie es aus namensrechtlichen Gründen nur in den USA und Kanada genannt wird oder Merck Sharp & Dohme (kurz MSD) ist ein US-amerikanisches Pharmaunternehmen mit Sitz in Kenilworth (New Jersey). Es war ursprünglich das US-amerikanische Tochterunternehmen des Darmstädter Pharmakonzerns E. Merck (heute Merck KGaA). Ebenso wie zahlreiche andere deutsche Vermögenswerte wurde es jedoch 1917 im Rahmen des Ersten Weltkrieges konfisziert und arbeitet seitdem unabhängig. Merck & Co. beschäftigt weltweit rund 69.000 Mitarbeiter[1] und ist mit knapp 40 Milliarden US-Dollar Umsatz weltweit – nach Pfizer, Roche und Novartis – einer der größten Arzneimittelhersteller der Welt.[3] In den Forbes Global 2000 der weltweit größten Unternehmen belegt Merck & Co. Platz 191 (Stand: Geschäftsjahr 2017). Das Unternehmen kam Mitte 2018 auf einen Börsenwert von über 160 Mrd. US$.[4]


https://de.wikipedia.org/wiki/Merck_%26_Co.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

...

Heading into today, shares of the pharmaceutical company had gained 5.58% over the past month, outpacing the Medical sector's gain of 3.15% and the S&P 500's gain of 0.89% in that time.

Investors will be hoping for strength from MRK as it approaches its next earnings release, which is expected to be February 1, 2019. In that report, analysts expect MRK to post earnings of $1.04 per share. This would mark year-over-year growth of 6.12%. Our most recent consensus estimate is calling for quarterly revenue of $11.05 billion, up 5.91% from the year-ago period.

For the full year, our Zacks Consensus Estimates are projecting earnings of $4.34 per share and revenue of $42.29 billion, which would represent changes of +9.05% and +5.41%, respectively, from the prior year.

...

https://finance.yahoo.com/news/merck-mrk...10192.html

MRK +1% new all time high 

Merck 4Q net powered by cancer treatment sales, lower taxes

Higher medicine sales and lower restructuring and other costs lifted drugmaker Merck to a $1.83 billion profit in the fourth quarter, as it edged past Wall Street expectations.

The maker of blockbuster cancer drug Keytruda and Januvia diabetes pills lost $1.05 billion a year earlier, when it had a $2.92 billion tax bill due to a federal tax overhaul.

...

The Kenilworth, New Jersey, drugmaker on Friday reported net income of 69 cents per share. Adjusted for multiple non-recurring costs, that amounted to $2.75 billion, or $1.04 per share, a penny better than analysts expected.

Revenue was $11 billion, slightly better than expected and up 5 percent from $10.43 billion in 2017's last quarter. Merck said unfavorable currency exchange rates reduced revenue by 3 percent in the quarter.

...

https://finance.yahoo.com/news/merck-4q-...ccounter=1

Merck Smashes Q1 Earnings Estimate, Boosts 2019 Outlook, as Keytruda Sales Surge

Merck posted stronger-than-expected first quarter earnings Tuesday, and lifted its 2019 profit guidance, as its blockbuster lung cancer treatment topped $2.2 billion.

...

Merck said GAAP earnings for the three months ending in March came in at $1.12 per share, more than four times higher than the same period last year and seven cents ahead of the Street consensus forecast. Group revenues, Merck said, rose 8% to $10.8 billion thanks in part to a 55% surge in sales of Keytruda lung cancer treatment.

...

https://www.thestreet.com/investing/earn...yptr=yahoo

Merck (MRK) Beats on Q3 Earnings & Sales, Raises '19 View

Merck & Co., Inc. MRK reported third-quarter 2019 adjusted earnings of $1.51 per share, which beat the Zacks Consensus Estimate of $1.25. Earnings rose 27% year over year on a reported basis as well as excluding the impact of currency.

Including acquisition- and divestiture-related costs, restructuring costs and certain other items, earnings per share were 74 cents compared with 73 cents in the year-ago quarter.

Revenues for the quarter rose 15% year over year to $12.4 billion, beating the Zacks Consensus Estimate of $11.7 billion. Currency movement negatively impacted revenues by 1%. Excluding currency impact, sales rose 16% year over year.


...

https://finance.yahoo.com/news/merck-mrk...02459.html

Merck (MRK) Beats on Q4 Earnings, Plans Women Health Spin Off

...Merck & Co., Inc. reported fourth-quarter 2019 adjusted earnings of $1.16 per share, which beat the Zacks Consensus Estimate of $1.14. Earnings rose 12% year over year. ...

...Revenues rose 8% year over year (9% excluding currency impact) to $11.9 billion, which missed the Zacks Consensus Estimate of $12.1 billion. Along with the earnings release, Merck announced that it will spin off products from its Women’s Health unit, legacy drugs (including Zetia and Vytorin) and biosimilar products into a new publicly traded company. ...

https://www.zacks.com/stock/news/750517/...quote_news

Merck's stock gains after profit and sales beat, but outlook is downbeat

...

Net income rose to $3.22 billion, or $1.26 a share, from $3.18 billion, or $1.12 a share, in the year-ago period. Excluding non-recurring items, adjusted earnings per share rose to $1.50 from $1.22, above the FactSet consensus of $1.34. Sales increased 11% to $12.06 billion to beat the FactSet consensus of $11.48 billion.

...

https://www.marketwatch.com/story/mercks...eid=yhoof2

Dividendenerhöhung um 6,56% | von 0,61 USD auf 0,65 USD
Ex-Tag 14.12.2020 | Zahltag 08.01.2021

Orales

Der Entwickler des Wirkstoffs hatte die Vorwürfe damals jedoch zurückgewiesen: Bei Tierstudien sei keine Veränderung des Erbguts beobachtet worden. Und trotz der erwähnten Sicherheitsbedenken laufen mittlerweile schon mehrere klinische Studien mit Molnupiravir. Der Pharmakonzern Merck etwa führt derzeit eine klinische Studie der fortgeschrittenen Phasen 2/3 mit mehr als 1000 Probanden durch. Ergebnisse werden allerdings erst für das kommende Jahr erwartet

https://www.n-tv.de/wissen/Neues-Corona-...20018.html

Coronavirus: Merck & Co berichtet von positiven Studienergebnissen bei seinem Covid-19-Medikament Molnupiravir. "Es ist ein schnellerer Virus-Rückgang bei Patienten in einem frühen Krankheitsverlauf festgestellt worden", wie das Unternehmen mitteilte / Quelle: Guidants News https://news.guidants.com